PainReform is a clinical-stage specialty pharmaceutical company that focuses on the reformulation of established therapeutics to improve pain management. Their proprietary technology, PRF-110, is a viscous, clear oil-based solution designed for direct instillation into surgical wounds. This innovative drug-delivery system aims to provide localized and extended post-operative analgesia, significantly enhancing patient comfort while minimizing the need for frequent opioid administration. The formulation's physical characteristics contribute to its tolerability and ease of use, setting it apart from currently marketed non-opiate extended relief products that often rely on complex formulations involving liposomes or artificial polymers.

The company has conducted a Phase 2 proof-of-concept study to evaluate the safety and efficacy of PRF-110 in hernia repair surgeries, demonstrating promising results. The study indicated that PRF-110 could reduce pain for up to 72 hours post-operatively, compared to the shorter relief provided by traditional pain medications like ropivacaine. Following positive outcomes from this study and extensive preclinical testing, PainReform has received FDA approval to initiate Phase 3 trials for PRF-110, targeting post-operative pain management in hernia repair and bunionectomy procedures. The company plans to expand its clinical focus to additional surgical indications, including various orthopedic and gynecological procedures, following successful commercialization of PRF-110.

Israel

PainReform Ltd. is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Their first product, PRF-110, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. The company is also involved in investor relations, stock performance, and earnings.

PainReform

Company Details